Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,517
  • Shares Outstanding, K 3,938
  • Annual Sales, $ 1,020 K
  • Annual Income, $ -18,460 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 0.50
  • Price/Sales 124.93
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 1
  • High Estimate -0.66
  • Low Estimate -0.66
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.92 +50.16%
on 12/01/25
35.22 -2.31%
on 12/10/25
+6.42 (+22.94%)
since 11/10/25
3-Month
18.97 +81.39%
on 09/17/25
35.22 -2.31%
on 12/10/25
+15.39 (+80.91%)
since 09/10/25
52-Week
13.15 +161.67%
on 12/30/24
35.22 -2.31%
on 12/10/25
+17.71 (+106.05%)
since 12/10/24

Most Recent Stories

More News
VTv Therapeutics: Q3 Earnings Snapshot

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 34.41 (+6.66%)
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced...

VTVT : 34.41 (+6.66%)
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , today announced the appointment...

VTVT : 34.41 (+6.66%)
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of...

VTVT : 34.41 (+6.66%)
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class...

VTVT : 34.41 (+6.66%)
vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class...

VTVT : 34.41 (+6.66%)
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type...

VTVT : 34.41 (+6.66%)
VTv Therapeutics: Q2 Earnings Snapshot

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 34.41 (+6.66%)
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual...

VTVT : 34.41 (+6.66%)
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of  cadisegliatin , a potential first-in-class...

VTVT : 34.41 (+6.66%)

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 41.25
2nd Resistance Point 38.24
1st Resistance Point 36.32
Last Price 34.41
1st Support Level 31.40
2nd Support Level 28.39
3rd Support Level 26.47

See More

52-Week High 35.22
Last Price 34.41
Fibonacci 61.8% 26.79
Fibonacci 50% 24.19
Fibonacci 38.2% 21.58
52-Week Low 13.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar